Writing in the journal Drug Safety, Besag et al conducted a systematic literature review to explore the current state of knowledge regarding tardive dyskinesia with antipsychotic medication in children and adolescents. The authors found 13 relevant studies, concluding that the risk of TD in this population is very real, despite a low overall incidence. There are limited treatment options for minors developing TD, leading the authors to conclude that “antipsychotics should be prescribed only if necessary, at the minimum effective dose and for the minimum necessary duration.”
Related Links:
— “Tardive Dyskinesia with Antipsychotic Medication in Children and Adolescents: A Systematic Literature Review,” Frank M. C. Besag, et.al., Drug Safety, June 11, 2024